Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

436 results about "Natural killer cell" patented technology

Natural killer cells, or NK cells, are a type of cytotoxic lymphocyte critical to the innate immune system. The role NK cells play is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. NK cells provide rapid responses to virus-infected cells, acting at around 3 days after infection, and respond to tumor formation. Typically, immune cells detect the major histocompatibility complex (MHC) presented on infected cell surfaces, triggering cytokine release, causing lysis or apoptosis. NK cells are unique, however, as they have the ability to recognize stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction. They were named "natural killers" because of the initial notion that they do not require activation to kill cells that are missing "self" markers of MHC class 1. This role is especially important because harmful cells that are missing MHC I markers cannot be detected and destroyed by other immune cells, such as T lymphocyte cells.

CD83-binding chimeric antigen receptors

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) in subjects receiving donor cells. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer suppress alloreactive donor cells. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

Humanized immunodeficient mouse model

PendingCN120051204ACompounds screening/testingUnknown materialsImmunodeficient mouse modelHuman cell
In some aspects, the disclosure provides humanized immunodeficient mouse models that support long term transplantation and function of human T cells, natural killer cells, and bone marrow cells without the need for conditioning.
Owner:JACKSON LAB THE +1

CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and / or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
Owner:NKARTA INC

Combined medicine for preventing and / or treating prostatic cancer, application of combined medicine and pharmaceutical composition

The invention belongs to the field of chemical medicines, and particularly relates to a combined medicine for preventing and / or treating prostatic cancer, application of the combined medicine and a medicine composition. The combined medicine disclosed by the invention comprises immune cells with enhanced infiltration degree and a galectin-1 inhibitor; the immune cells with enhanced infiltration degree are natural killer (NK) cells with TTTY15-USP9Y chimera RNA knocked out, the infiltration degree and anti-tumor activity of the NK cells in a prostate cancer microenvironment can be improved, and the activated NK cells have a stronger killing effect on tumor cells in vitro. The immune cells with enhanced infiltration degree and the galectin-1 inhibitor are combined for use, so that the composition shows a synergistic effect in treatment of prostatic cancer, and has a wide application prospect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Compositions and methods for immune cell modulation in adoptive immunotherapies

Compounds that either produced a higher proportion or greater absolute number of phenotypically identified naïve, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
Owner:FATE THERAPEUTICS INC

Method of treating alzheimer's disease with expanded natural killer cells

A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
Owner:NKMAX CO LTD

Method of treating parkinson's disease with expanded natural killer cells

Provided herein is a method for treating Parkinson's disease (PD). The method can include identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating PD.
Owner:NKMAX CO LTD

Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
Owner:NOVARTIS AG +1

Gene editing target gene to enhance natural killer cell function

Several embodiments of the methods and compositions disclosed herein relate to immune cells that are gene edited (e.g., using Crispr / Cas) to modulate, reduce, or otherwise eliminate expression of one or more endogenous genes. In several embodiments, the edited cells are engineered to express chimeric antigen receptors that target tumor antigens (e.g., CD19, ligands of the NKG2D receptor, CD70, and / or BCMA, etc.). In several embodiments, the editing enhances one or more aspects of immune cell efficacy in cellular immunotherapy, including cytotoxicity (e.g., ADCC) and / or persistence.
Owner:NKARTA INC

Il-12 activates NK cells transfected with car RNA-lnp

The present disclosure provides a method for preparing natural killer (NK) cells with increased secretion of cytokines and increased cytotoxicity. The present invention uses IL-12 during transfection to generate CAR-NK cells with increased functional activities (cytotoxicity and secretion of cytokines) against tumor cells.
Owner:PROMAB BIOTECH +1

CD19 and CD22 chimeric antigen receptors and uses thereof

The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and / or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and / or CD19, methods of making a cell comprising the same and vectors encoding the same.
Owner:NOVARTIS AG

Antibodies to TIGIT

The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.
Owner:ARCUS BIOSCIENCES INC

Methods for enhancement of engineered cell therapies in cancer treatment

Methods are provided for reprogramming M2-like macrophages to M1-like macrophages, which reverses the proinflammatory to anti-inflammatory shift observed during the course of certain cancers, co-administered with one or more types of engineered cells such as, without limitation, CAR T-cells, engineered natural killer cells, engineered stem cells or the like. The compounds comprise an immune modulator that targets a pattern recognition receptor of a cell and are specific to the cells of interest through the incorporation of a targeting moiety (e.g., folate or a functional fragment or analog thereof). Releasable and / or non-releasable linkers can be included and engineered to facilitate the optimal delivery of the immune modulator. The compounds and compositions can be employed in one or more methods of treatment for cancers.
Owner:PURDUE RES FOUND

Fusion protein comprising il-2 protein and CD80 protein, and use thereof

Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.
Owner:GI INNOVATION INC

Universal T cells and the method of use thereof

A series of recombinant DNA constructs and a method is disclosed for use in immunological therapy in general; and in disrupting T cell receptor (TCR), human leukocyte antigens (HLA) class I and NKG2D (Natural-Killer Group 2, member D) ligand expression in particular, with the effect of producing highly compatible autologous universal T cells for further genetically engineering for allogeneic administration. A Universal T (UT) construct is provided and used, comprising a TCR antibody fragment fused to a transmembrane domain (TMD) and ER retention domain of adenovirus early region 3 glycoprotein E3-19k (E3 / 19K) (TCR-E3 / 19K RD). The Universal T (UT) construct can hijack ERAD machinery to arrest TCR and HLA molecules in endoplasmic reticulum (ER) and facilitate their translocation into the cytoplasm for ubiquitination and degradation by proteasomes.
Owner:ST PHI THERAPEUTICS +1

Fermentate with anti-inflammatory and immune modulating properties

ActiveUS12370227B1AntipyreticAnalgesicsDecreased T cell activationFermentation
A fermentation process is disclosed that produces an immunomodulatory product. The process includes combining a source of starch, a source of sugar, and a source of a trace mineral with probiotic microorganisms and fermenting aerobically and anaerobically, thereby producing an immunomodulatory product. Turmeric is added before or after fermentation. The immunomodulatory product is also disclosed. Also provided are uses of the immunomodulatory product, such as to decrease inflammation in a subject. These methods can include increasing function of natural killer cells, decreasing T cell activation, altering CD69 expression on immune cells, and / or altering cytokine expression in a subject.
Owner:ITE INVESTMENTS LLC

CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and / or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
Owner:NKARTA INC

Use of isatuximab in combination with other agents for the treatment of multiple myeloma

The present disclosure provides methods for treating multiple myeloma comprising administering an anti-CD38 antibody and an Interleukin-2 analog to an individual in need thereof and optionally administering Natural Killer (NK) cells having expression of CD38 reduced or knocked-out.
Owner:SANOFI AVENTIS US LLC

Lung-targeted exosome complex as well as preparation method and application thereof

The invention relates to the technical field of novel biological nanomaterials, in particular to a lung-targeted exosome complex as well as a preparation method and application thereof. The lung targeting type exosome complex is prepared from an NK cell exosome, lipid nanoparticles and an entrapped anti-tumor nucleic acid drug, the NK cell exosome is obtained by extracting a natural killer cell NK-92MI of a human malignant non-Hodgkin lymphoma patient through a differential centrifugation method. The anti-tumor nucleic acid drug is a specific nucleic acid drug targeting a key canceration driving gene in non-small cell lung cancer. The lung targeting type exosome complex prepared by the invention is an excellent and stable drug delivery carrier, has a good lung tissue targeting function, enhances the tumor targeting effect of the exosome, also exerts the tumor cell killing function of the exosome, and has important significance for the treatment of non-small cell lung cancer.
Owner:BEIJING INST OF TECH

Stealth lipid nanoparticle compositions for cell targeting

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Owner:GENERATION BIO CO

Composition comprising mixture of exosomes as active ingredient and use thereof

The present invention relates to a composition comprising a mixture of exosomes derived from different cells, as an active ingredient and use thereof. More specifically, the present invention relates to a composition for treating skin diseases and / or improving skin conditions, comprising, as an active ingredient, mixed exosomes or fused exosomes in which natural killer cell-derived exosomes and mesenchymal stem cell-derived exosomes are mixed or fused. The composition according to the present invention exhibits an excellent cell proliferation effect and the effect of promoting collagen production, and thus can be effectively used as not only a cosmetic material for improving skin conditions, such as by reducing skin wrinkles, regenerating wounds, and increasing elasticity, but also a pharmaceutical material for preventing or treating skin diseases such as atopic dermatitis.
Owner:THERABEST CO LTD

GiNK cell culture method

The invention provides a method for obtaining GiNK cells through novel culture medium amplification, a large number of highly purified human natural killer (NK) cells are obtained by combining IL-15 active fragments, PI3K inhibitors, key receptors targeting the surfaces of the NK cells, antibodies enhancing activation of the NK cells and various cytokines, and the GiNK cells can be used for preparing the human natural killer cells. Expansion from human peripheral blood mononuclear cells (PBMCs) can be achieved without the use of feeder cells. Through culture for 2-3 weeks, the GiNK cells can be amplified by hundreds to thousands of times, and the proliferation efficiency, functional activity and anti-tumor effect of the GiNK cells are remarkably improved. The culture medium provided by the invention not only reduces the use concentration of cell factors, but also solves the problem of function depletion of GiNK cells in in-vitro culture through the synergistic effect of various additives, and provides important technical support for clinical application of the GiNK cells.
Owner:SHANGHAI ZHIQUAN BIOTECHNOLOGY CO LTD

Combination therapy of bispecific anti-EGFR / c-Met antibodies and anti-PD-1 antibodies

The present invention relates to combination therapies for modulating the tumor microenvironment and enhancing infiltration of immune cells into the tumor microenvironment with a bispecific anti-EGFR / c-Met antibody in combination with a PD-(L) 1 axis inhibitor. The invention also relates to combination therapies for inhibiting EGFR and MET signaling pathways in tumor cells, and targeting tumor cells expressing EGFR and MET to be disrupted by immune effector cells such as natural killer cells and macrophages by antibody dependent cytotoxicity (ADCC) and cell gnawing mechanisms, respectively.
Owner:JANSSEN BIOTECH INC

Anticancer cell therapy technique targeting pericytes of tumor microenvironment by using natural killer cells in which chimeric antigen receptor is expressed, and technology for producing tumor microenvironment organoid model for evaluating therapeutic efficacy

The present invention relates to an anticancer cell therapy technique targeting pericytes of tumor microenvironment by using natural killer cells in which a chimeric antigen receptor is expressed, and a technique for producing a tumor microenvironment organoid model for evaluating therapeutic efficacy, and, more specifically, provides: a pharmaceutical composition for preventing or treating cancer, comprising natural killer cells in which a CD19 chimeric antigen receptor is expressed; a glioblastoma-vascular fusion organoid prepared by co-culturing a vascular organoid and glioblastoma spheroids; a microcirculation chip on which the glioblastoma-vascular fusion organoid is mounted; and an animal model to which the glioblastoma-vascular fusion organoid is xenografted.
Owner:SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Composition for enhancing immunity comprising polysaccharide enzyme-treated product or purified fraction thereof

PCT designated stageWO2026135372A1Food shapingBiotechnologyAngelica gigas
The present invention relates to a composition for enhancing immunity, containing, as an active ingredient, a polysaccharide enzyme-treated product derived from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified polysaccharide fraction thereof. The composition for enhancing immunity according to the present invention, comprising the polysaccharide enzyme-treated product of the mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora or the novel purified polysaccharide fraction thereof, is composed of specific types and contents of sugars and significantly increases the activity of macrophages, splenocytes, and NK cells upon application thereto, thereby being applicable as an immunopotentiator or a composition for enhancing immunity.
Owner:KOLMAR BNH CO LTD